Synairgen (GB:SNG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Synairgen plc has announced that Dr. Phillip Monk will be stepping down from the company’s Board after 18 years, effective December 31, 2024. Dr. Marcin Mankowski, who became Chief Medical Officer in 2023, will continue leading the clinical development of SNG001, Synairgen’s investigational inhaled antiviral treatment. The company also hints at upcoming Board changes as it prepares for its Annual General Meeting in early October.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.